COVID-19 Therapy (Severe)
Phase 3 (Expanded Access)
Amp Volatility Score
Catalyst Info & Data Links
TITLE: Remdesivir in COVID-19 (Severe)
ClinicalTrial.gov (NCT04292899): Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)
WHAT IS THE CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
April 29, 2020: Phase 3 Topline Data
2020: Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. Journal of Korean medical science, 35(6).
Updated by HC
#GILD, #Remdesivir , #COVID19
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post